COR Stock: Price, Earnings History and SEC Filings
Cencora, Inc. (COR) last traded at $330.84, up 0.09% on the latest session and up 10.2% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $4.48 against an analyst estimate of $4.37, a beat of 2.5%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
COR earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $4.48 | $4.37 | +2.52% |
| Mar 2026 | May 6, 2026 | $4.75 | $4.80 | -1.04% |
| Dec 2025 | Feb 4, 2026 | $4.08 | $4.07 | +0.25% |
| Sep 2025 | Nov 5, 2025 | $3.84 | $3.79 | +1.32% |
COR beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How COR reacts to earnings
Across its last 8 earnings releases, COR moved 5.2% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-21 | Before open | -0.83% |
| 2026-08-05 | Before open | +3.57% |
| 2026-05-06 | Before open | -17.38% |
| 2026-02-04 | Before open | -8.79% |
| 2025-11-05 | Before open | +2.75% |
| 2025-08-06 | Before open | -2.93% |
| 2025-05-07 | Before open | +4.74% |
| 2025-02-05 | Before open | +0.68% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
COR financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $321.3B | $1.6B | $3.2B | 0.5% | $7.96 |
| 2024 | $294.0B | $1.5B | $3.0B | 0.5% | $7.53 |
| 2023 | $262.2B | $1.7B | $3.5B | 0.7% | $8.53 |
| 2022 | $238.6B | $1.7B | $2.2B | 0.7% | $8.04 |
| 2021 | $214.0B | $1.5B | $2.2B | 0.7% | $7.39 |
| 2020 | $189.9B | -$3.4B | $1.8B | -1.8% | $-16.65 |
| 2019 | $179.6B | $855M | $2.0B | 0.5% | $4.04 |
| 2018 | $167.9B | $1.7B | $1.1B | 1.0% | $7.53 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for COR
- 8-K · Oct 21, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Sep 25, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Aug 14, 2026Officer or director change
- 8-K · Aug 12, 2026Regulation FD disclosure
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Material agreement, New financial obligation, Financial statements and exhibits
- 8-K · Aug 5, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jun 15, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 8-K · May 29, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 10-Q · May 6, 2026
Insider filing activity
COR insiders filed 8 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
COR news
- Cencora (COR) Stock Still Looks Undervalued After Its 173% RunNov 1, 2026 · finance.yahoo.com
- Is Cencora (COR) Fully Valued Following Its $2.4b American Oncology Network Deal?Nov 1, 2026 · finance.yahoo.com
- What Does Cencora (COR) Gain From Expanding Into 12 More States?Oct 31, 2026 · finance.yahoo.com
- 2 large-cap stocks with impressive fundamentals and 1 we ignoreOct 30, 2026 · finance.yahoo.com
- Cencora Gears Up to Report Q4 Results: How to Play the Stock?Oct 30, 2026 · finance.yahoo.com
- Unveiling Cencora (COR) Q4 Outlook: Wall Street Estimates for Key MetricsOct 30, 2026 · finance.yahoo.com
- Is Buying McKesson Stock Near Its High A Bad Idea?Oct 30, 2026 · trefis.com
- Is It A Mistake To Buy Cardinal Health Stock At A High?Oct 29, 2026 · trefis.com
About Cencora, Inc.
Cencora, Inc. (COR) is a US-listed public company on NYSE. The SEC classifies its business as Wholesale-drugs Proprietaries & Druggists' Sundries. It is incorporated in DE. Its fiscal year ends in September.